However, as no screening tools currently exist even for BRCA1 mutation carriers, who have a 40% lifetime risk of ovarian cancer, we think that developing a screening tool with high sensitivity and negative predictive value in high-risk populations alone would already be a significant step forward. This evidence concerns the gene BRCA1 and ovarian carcinoma.